Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Roberto Castelli, Antonino Cannavò, Fabio Conforti, Giovanni Grava & Agostino Cortelezzi. (2012) Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice. Immunopharmacology and Immunotoxicology 34:5, pages 740-753.
Read now
Read now
E. M. Weiss, S. Meister, C. Janko, N. Ebel, E. Schlücker, R. Meyer-Pittroff, R. Fietkau, M. Herrmann, U. S. Gaipl & B. Frey. (2010) High hydrostatic pressure treatment generates inactivated mammalian tumor cells with immunogeneic features. Journal of Immunotoxicology 7:3, pages 194-204.
Read now
Read now
Maurizio Chiriva-Internati, Everardo Cobos & W. Martin Kast. (2007) Advances in Immunotherapy of Multiple Myeloma: From the Discovery of Tumor-Associated Antigens to Clinical Trials. International Reviews of Immunology 26:3-4, pages 197-222.
Read now
Read now
Articles from other publishers (10)
Alessandro Allegra, Giuseppa Penna, Vanessa Innao, Bruna Greve, Valerio Maisano, Sabina Russo & Caterina Musolino. (2015) Vaccination of multiple myeloma: Current strategies and future prospects. Critical Reviews in Oncology/Hematology 96:2, pages 339-354.
Crossref
Crossref
Qing Yi. 2013. Advances in Biology and Therapy of Multiple Myeloma. Advances in Biology and Therapy of Multiple Myeloma
25
42
.
S Hong, H Li, J Qian, J Yang, Y Lu & Q Yi. (2012) Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity. Clinical and Experimental Immunology 170:2, pages 167-177.
Crossref
Crossref
Sungyoul Hong, Jianfei Qian, Haiyan Li, Jing Yang, Yong Lu, Yuhuan Zheng & Qing Yi. (2011) CpG or IFN-α are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma. Cancer Immunology, Immunotherapy 61:4, pages 561-571.
Crossref
Crossref
Qing Yi, Susann Szmania, John Freeman, Jianfei Qian, Nancy A. Rosen, Sanjaya Viswamitra, Michele Cottler‐Fox, Bart Barlogie, Guido Tricot & Frits Van Rhee. (2010) Optimizing dendritic cell‐based immunotherapy in multiple myeloma: intranodal injections of idiotype‐pulsed CD40 ligand‐matured vaccines led to induction of type‐1 and cytotoxic T‐cell immune responses in patients. British Journal of Haematology 150:5, pages 554-564.
Crossref
Crossref
Qing Yi. (2009) Novel Immunotherapies. The Cancer Journal 15:6, pages 502-510.
Crossref
Crossref
Shiri Moshitzky, Tova Kukulansky, Joseph Haimovich & Nurit Hollander. (2008) Growth inhibition of myeloma cells by anti‐idiotype antibodies in the absence of membrane‐bound immunoglobulin. Immunology & Cell Biology 86:3, pages 261-267.
Crossref
Crossref
Jianfei Qian, Siqing Wang, Jing Yang, Jin Xie, Pei Lin, Muta E. FreemanIIIIII & Qing Yi. (2005) Targeting Heat Shock Proteins for Immunotherapy in Multiple Myeloma: Generation of Myeloma-Specific CTLs Using Dendritic Cells Pulsed with Tumor-Derived gp96. Clinical Cancer Research 11:24, pages 8808-8815.
Crossref
Crossref
Ali JaliliShuji OzakiTomoko HaraHironobu ShibataToshihiro HashimotoMasahiro AbeYasuhiko NishiokaToshio Matsumoto. (2005) Induction of HM1.24 peptide–specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma. Blood 106:10, pages 3538-3545.
Crossref
Crossref
F. Owotade, V. Ugboko, S. Ajike, L. Salawu, Y. Amusa & M. Omole. (2005) Head and neck manifestations of myeloma in Nigerians. International Journal of Oral and Maxillofacial Surgery 34:7, pages 761-765.
Crossref
Crossref